Priya Shetty answers some common questions surrounding antibiotic resistance, and the dangers for the developing world.
Since the development of the first antibiotics 50 years ago (see Box 1) the world has come to rely on these drugs to vanquish the many varieties of disease-causing bacteria. Their absence would have grave implications for the health of all populations, but particularly those of developing countries.
Unfortunately, the effectiveness of antibiotics is under threat. Around the world, bacteria are mutating to defend themselves against drugs that would once have killed them. This is not unexpected — organisms constantly evolve to find ways to adapt to new circumstances. What is threatening global health is the speed with which some strains are developing resistance.
Because of the enormous worldwide use of antibiotics — for example, in pills to treat human illness or as growth promoters for food animals — bacteria are adapting to modern antibiotics faster than we can create new ones.
How do bacteria become resistant to antibiotics?
Bacteria develop resistance in different ways but they all involve either a change in their existing genetic material (known as spontaneous mutation) or the acquisition of new genetic material. The addition of new material can happen when bacteria-specific viruses (called bacteriophages) transfer DNA between two closely related bacteria. Bacteria can also absorb the DNA of bacteria in its vicinity. The most common way in which DNA can be exchanged is when small pieces of DNA called plasmids are moved between bacteria in direct contact.
- Altering membrane pumps. Some antibiotics collect inside the bacteria to kill it. The bacteria in turn have pumps on their cell membrane to get rid of the drug. Usually, the bacteria can't pump the drug out fast enough. But if a mutation enables the bacteria to produce more pumps than normal, the drug can be ejected from the cell before it takes effect.
- Destroying the antibiotic with enzymes. A bacterial enzyme can destroy a key component of the antibiotic, rendering it useless. Lactamase, for example, can target the core of penicillin. Scientists are now adding 'enzyme-silencers' — such as clavulanic acid for penicillin — to make sure the antibiotic continues to work.
- Moving the target. The bacteria can change the molecules that the drug targets. The antibiotic would normally attach to this, so altering it stops the antibiotic from taking hold.
Figure 1. Mechanisms of antibiotic resistance
Credit: The Science Creative Quarterly (http://www.scq.ubc.ca/)/Fan Sozzi
Why are antibiotics so vital for the developing world?
Unlike developed countries, where people have easy access to antibiotics, many people in developing nations — which tend to have poor healthcare systems, poor infrastructure and few resources — die from diseases that are easily treatable. Illnesses such as tuberculosis (TB) can be fatal if left untreated and, by weakening immune systems, they can make people vulnerable to severe infectious diseases, such as HIV/AIDS and malaria.
TB alone kills 1.6 million people every year — 98 per cent of whom live in developing countries (see figure 2). [1–3] Data on resistance to TB drugs indicates that 3.2 per cent of all new cases are multidrug resistant.  Around 70 million people could be infected with latent (i.e. not active) multidrug-resistant TB. 
Bacterial sexual diseases are still major health concerns in the developing world. Between three and 18 per cent of pregnant women attending antenatal centres in Africa have syphilis. Even in low-risk populations in Africa, 40 per cent have infections like gonorrhoea and chlamydia. Penicillin resistance in Neisseria gonorrhoeae — the bacteria causing gonorrhoea — can be as high as 90 per cent in Asia, and is higher than 35 per cent in Sub-Saharan Africa and the Caribbean. Women who have antibiotic-resistant gonorrhoea are at risk of pelvic inflammatory disease and infertility, which can increase the chance of HIV transmission. [5,6]
In many developed countries, antibiotic-resistant infections such as MRSA transmitted in hospitals have grabbed headlines. In developing countries, resource constraints, overcrowding and inadequate medical supplies can increase the risk of patients being infected with resistant bacteria. Estimates from South Africa suggest that hospital infection rates in developing countries are about 15 per cent, making it a key cause of death. 
Why is resistance on the rise?
Some of the reasons for the growth of antibiotic resistance — such as overuse or misuse — are common to all countries, but developing countries have unique factors that tend to be absent in developed nations.
For example, prescribing the right antibiotics for a bacterial illness requires accurate diagnosis. In many poor countries, such diagnostics are simply non-existent. Faced with a sick patient but no way of finding out exactly what they are infected with, doctors will often make an educated guess at the cause of illness or prescribe an antibiotic that targets several bacteria.
Patients are also often not educated about why they should complete their course of antibiotics (although this is by no means unique to developing countries). A Mexican study found that 60 per cent of patients did not adhere to their prescribed regimens. 
Developing countries often have limited access to drugs, and poor infrastructure can mean supplies are erratic. Even when drugs are available, people might not be able to afford them, and so resort to buying them from untrained vendors or street hawkers. A Vietnamese study reported that 72 per cent of drug purchases were made without prescription. 
Antibiotics sold illegally can be counterfeit and contain no active ingredient; worse still, they can sometimes contain a small amount of the active ingredient, which is not enough to kill the bacteria but is enough for them to develop an immunity to it, thus increasing resistance. Counterfeit drugs account for 6–20 per cent of all drug sales, most of which are antibiotics. 
Causes of antibiotic resistance in developed countries — the growing use of antibacterial detergents, and pressures on doctors from patients who want to be prescribed antibiotics regardless of whether they are necessary — are also relevant to developing countries. Global travel means that antibiotic-resistant bacteria are not confined to the country in which they originate.
Why can't we just make more?
An obvious question is why drug companies can't simply produce more antibiotics. Firstly, developing new drugs is enormously expensive. It costs about US$900 million to bring a drug from research to market. The investment needed to research and produce these drugs can sometimes cost far more than the companies are ever likely to see from drug sales.
Experts estimate that research and development into antibiotics has fallen by about 60 per cent in the past decade.  Given a choice between focusing on antibiotics or other drugs that are likely to yield a better return, pharmaceutical companies understandably often choose the latter.
Even if drug companies were given more incentive to research new antibiotics, one barrier is the growing difficulty of discovering new drug classes. In the early days of antibiotic development, new classes were identified every few years, but inevitably this has slowed down.
Figure 2. Prevalence of multidrug-resistant tuberculosis in new tuberculosis cases between 1994 and 2000
Source: The Lancet Infectious Diseases/WHO
Box 1: Timeline of antibiotic development
1928 Alexander Fleming discovers the antibacterial properties of penicillin in mould.
 TB Alliance. The threat of TB. Available at: http://www.tballiance.org/why/tb-threat.php (25 February 2008)
 The World Health Organization. TB — a global emergency, WHO report on the TB epidemic (1994)
 The World Health Organization. Global tuberculosis control — surveillance, planning, financing (2004)
 Dye C., Espinal M.A. Will tuberculosis become resistant to all antibiotics? Proceedings of the Royal Society B: Biological Science 268: 45–52 (2001)
 Okeke I.N., et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. The Lancet Infectious Diseases 5, 481–93 (2005)
 Urdea M. et al. Requirements for high impact diagnostics in the developing world. Nature 444, 73–79 (2006)
 Reyes H., et al. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. Journal of Clinical Epidemiology 50, 1297–1304 (1997).
 Larsson M., et al. Antibiotic medication and bacterial resistance to antibiotics: a survey of children in a Vietnamese community. Tropical Medicine & International Health 5, 711–721 (2000)
 Okeke I.N., et al. Antimicrobial resistance in developing countries. Part II: strategies for containment. The Lancet Infectious Diseases 5: 568–76 (2005)
 Bailey P. In the pipeline: New agents to combat bacterial infections http://www.wellcome.ac.uk/doc_WTX026129.html (25 February 2005)